Roche, Isis Join 'Hunt' for Brain Cures in $392M Partnership
Isis Pharmaceuticals Inc. and Roche AG have partnered to develop therapies for Huntington's disease using Isis antisense oligonucleotide (ASO) technology. The two companies will also work together to increase brain penetration of ASOs. Roche will pay $30 million up front to Isis, with milestone payments up to $362 million, including $80 million in commercial milestones.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter